Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-08-11
2008-12-16
Habte, Kahsay T (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S220000, C540S554000, C540S577000
Reexamination Certificate
active
07465722
ABSTRACT:
A compound of the formulae (I) or (II):wherein:Y is a moiety selected from NR or —(CH2)n;wherein R is hydrogen or (C1-C6) lower alkyl,and n is 1;represents:(1) a phenyl ring optionally substituted with one or two substituents selected, independently, from the group comprising hydrogen, (C1-C6) lower alkyl, halogen, cyano, CF3, hydroxy, (C1-C6) lower alkoxy, (C1-C6) lower alkoxy carbonyl, carboxy, —CONH2, —CONH[(C1-C6) lower alkyl], —CON[(C1-C6) lower alkyl]2; or(2) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C1-C6) lower alkyl, halogen or (C1-C6) lower alkoxy;represents:(1) a phenyl ring optionally substituted with one or two substituents selected, independently, from the group comprising hydrogen, (C1-C6) lower alkyl, halogen, cyano, CF3, hydroxy, (C1-C6) lower alkoxy, or (C1-C6) lower alkoxy carbonyl, carboxy, —CONH2, —CONH[(C1-C6) lower alkyl], —CON[(C1-C6) lower alkyl]2; or(2) a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C1-C6) lower alkyl, (C1-C6) lower alkoxy, or halogen; or(3) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C1-C6) lower alkyl, halogen, or (C1-C6) lower alkoxy;represents a 5-membered aromatic (unsaturated) heterocyclic ring having one sulfur atom, optionally substituted by (C1-C6) lower alkyl, halogen, or (C1-C6) lower alkoxy;R1is a moiety of the formulaand R2, R3, R7, R8and R9are, independently, selected from a group consisting of hydrogen, (C1-C3) lower alkyl, OCH3, halogen, CF3, —SCH3, OCF3, SCF3, or CN;or a pharmaceutically acceptable salt, or pro-drug form thereof.
REFERENCES:
patent: 5516774 (1996-05-01), Albright
patent: 5521173 (1996-05-01), Venkatesan et al.
patent: 5532235 (1996-07-01), Albright
patent: 5536718 (1996-07-01), Albright
patent: 5610156 (1997-03-01), Albright
patent: 5612334 (1997-03-01), Albright
patent: 5624923 (1997-04-01), Albright
patent: 5654297 (1997-08-01), Albright
patent: 5686445 (1997-11-01), Albright
patent: 5693635 (1997-12-01), Albright
patent: 5696112 (1997-12-01), Albright et al.
patent: 5700796 (1997-12-01), Albright
patent: 5719278 (1998-02-01), Albright
patent: 5733905 (1998-03-01), Albright
patent: 5736538 (1998-04-01), Albright
patent: 5736540 (1998-04-01), Albright
patent: 5739128 (1998-04-01), Albright
patent: 5747487 (1998-05-01), Albright
patent: 5753648 (1998-05-01), Albright
patent: 5760031 (1998-06-01), Albright
patent: 5780471 (1998-07-01), Venkatesan et al.
patent: 5849735 (1998-12-01), Albright et al.
patent: 6096736 (2000-08-01), Ogawa
patent: 6194407 (2001-02-01), Shumsky et al.
patent: WO 95/34540 (1995-12-01), None
patent: WO 96/22282 (1996-07-01), None
patent: WO 97/22591 (1997-06-01), None
patent: WO 99/65525 (1999-12-01), None
patent: WO 00/43398 (2000-07-01), None
patent: WO 00/46227 (2000-08-01), None
Wolff Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York. 1996, pp. 451 and 596.
Beitz, et al., “The mammalian aquaporin water channel family: A promising new drug target”, Curr Med Chem. Jun. 1999;6(6):457-67.
Goodman and Gilman, The Pharmacological Basis of Therapeutics, 1966, 715-731, 9th Edition.
Lethagen, Ann Hematol., 1994, 173-180, 69.
Cash et al., Brit. J. Haematol., 1974, 363-364, 27.
David, Regulatory Peptides, 1993, 311-317, 45.
Burggraff et al., Cli. Sci., 1994, 497-503, 86.
Caggiano Thomas J.
Dusza John P.
Failli Amedeo A.
Memoli Kevin A.
Shumsky Jay S.
Habte Kahsay T
Pepper Hamilton LLP
Wyeth
LandOfFree
Biphenyl vasopressin agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biphenyl vasopressin agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biphenyl vasopressin agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4035009